NCT07051447Not yet recruiting
The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial
The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial (RADAR-K): A Randomized, Controlled, Pilot Trial Comparing Usual Care to a Precision Approach to Dialysis Potassium Prescribing.
Source: ClinicalTrials.gov · Last updated 4 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This will be a randomized controlled pilot trial comparing usual care to a precision approach to dialysis potassium prescribing. The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 26 Jun 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 1 Feb 2029
- Lead sponsor
- NYU Langone Health
- Diseases
- Chronic kidney disease
- NCT number
- NCT07051447
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 1 Aug 2025 to the primary completion date, 1 Feb 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Kidney transplant, transition to home dialysis, or transfer to non-participating HD unit anticipated within 6 months or less
- Participation in other interventional studies within 30 days prior to enrollment
Other illness
- Cognitive condition that precludes consent
Lab values
- Severe anemia (hemoglobin \< 8.0 g/dL) within 30 days
Other
- Incarcerated
- Life expectancy of 1 year or less
- K concentration of 7.0 mEq/L or more within 60 days
- Pregnant women
- Women of childbearing potential actively trying to conceive unwilling to use contraception
Who the study is looking for
- Undergoing in-center, 3x/weekly HD for treatment of end-stage kidney disease (ESKD) for at least 90 days
- Age at least 21 years
- Prescribed HD time up to 15 hours/ week
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.